Why Patients Are Being Forced to Switch to a 2nd-Choice Obesity Drug

Health
By Rebecca Robbins and Reed Abelson from NYT Health https://ift.tt/aELAuXf
via IFTTT GLP-1 RAs (Drug), Drugs (Pharmaceuticals), Prices (Fares, Fees and Rates), Health Insurance and Managed Care, Weight, Obesity, Research, Clinical Trials CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed by insurance that disrupt treatments for patients.

Comments

Popular posts from this blog

U.S. Quietly Drafts Plan to End Program That Saved Millions From AIDS

The Jarring Contradiction at the Heart of Kennedy’s Agenda